These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 6811133

  • 1. The development of new cancer drugs: a joint venture in public policy by the National Cancer Institute and Food and Drug Administration.
    Crout JR.
    Cancer Treat Rep; 1982 Sep; 66(9):1705-7. PubMed ID: 6811133
    [No Abstract] [Full Text] [Related]

  • 2. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S, Wittes R.
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract] [Full Text] [Related]

  • 3. Preclinical toxicology of anticancer agents.
    Schein PS.
    Cancer Res; 1977 Jun; 37(6):1934-7. PubMed ID: 404039
    [No Abstract] [Full Text] [Related]

  • 4. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS.
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [Abstract] [Full Text] [Related]

  • 5. The clinical toxicity of anticancer drugs and its prediction.
    Creaven PJ, Mihich E.
    Semin Oncol; 1977 Jun; 4(2):147-63. PubMed ID: 406677
    [No Abstract] [Full Text] [Related]

  • 6. Fast track for AIDS and cancer drugs.
    Gershon D.
    Nature; 1990 Aug 23; 346(6286):685. PubMed ID: 2388690
    [No Abstract] [Full Text] [Related]

  • 7. Chemotherapy research nurse.
    Hubbard S, Devita V.
    Am J Nurs; 1976 Apr 23; 76(4):560-5. PubMed ID: 818899
    [No Abstract] [Full Text] [Related]

  • 8. Waiting for a philosopher king: making cancer policy until certainty arrives.
    Speth G.
    Tex Rep Biol Med; 1978 Apr 23; 37():95-106. PubMed ID: 752987
    [No Abstract] [Full Text] [Related]

  • 9. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM.
    Cancer Treat Rep; 1983 Sep 23; 67(9):767-72. PubMed ID: 6883352
    [No Abstract] [Full Text] [Related]

  • 10. Advances in the clinical development of antiepileptic drugs.
    Porter RJ, Hessie BJ, Cereghino JJ, Gladding GD, Kupferberg HJ, Scoville B, White BG.
    Fed Proc; 1985 Jul 23; 44(10):2645-9. PubMed ID: 3891417
    [Abstract] [Full Text] [Related]

  • 11. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
    Hansen K, Khanna C.
    Eur J Cancer; 2004 Apr 23; 40(6):858-80. PubMed ID: 15120042
    [Abstract] [Full Text] [Related]

  • 12. Multi-species toxicology approaches for oncology drugs: the US perspective.
    Tomaszewski JE.
    Eur J Cancer; 2004 Apr 23; 40(6):907-13. PubMed ID: 15120046
    [Abstract] [Full Text] [Related]

  • 13. Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: dose formulation.
    Davignon JP.
    Cancer Chemother Rep 3; 1972 May 23; 3(1):77-8. PubMed ID: 5068318
    [No Abstract] [Full Text] [Related]

  • 14. Toxicology of anticancer drugs.
    Guarino AM.
    Natl Cancer Inst Monogr; 1977 Mar 23; (45):49-55. PubMed ID: 412105
    [No Abstract] [Full Text] [Related]

  • 15. The linear array.
    Zubrod CG, Schepartz SA, Carter SK.
    Natl Cancer Inst Monogr; 1977 Mar 23; (45):13-4. PubMed ID: 927488
    [No Abstract] [Full Text] [Related]

  • 16. The role of the National Cancer Institute in drug development.
    Doroshow J.
    Clin Adv Hematol Oncol; 2005 Apr 23; 3(4):257-8. PubMed ID: 16166997
    [No Abstract] [Full Text] [Related]

  • 17. [Introduction of new screening system in National Cancer Institute].
    Tsukagoshi S.
    Gan To Kagaku Ryoho; 1984 May 23; 11(5):1134-9. PubMed ID: 6539100
    [No Abstract] [Full Text] [Related]

  • 18. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Staquet MJ, Byar DP, Green SB, Rozencweig M.
    Cancer Treat Rep; 1983 Sep 23; 67(9):753-65. PubMed ID: 6883351
    [Abstract] [Full Text] [Related]

  • 19. Joint FDA, NCI program aims to streamline cancer drug development.
    FDA Consum; 2003 Sep 23; 37(4):11. PubMed ID: 12971341
    [No Abstract] [Full Text] [Related]

  • 20. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
    Mol Interv; 2007 Dec 23; 7(6):325-34. PubMed ID: 18199854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.